Developing an integrated care pathway for implementing disease-modifying therapies in Alzheimer’s
For the past 20 years, no new licensed drugs have been available for Alzheimer’s disease. Soon, disease-modifying therapies (DMTs) will be available in Ireland to slow its progression. However, these expensive drugs require significant changes in our healthcare system. An implementation plan, or care pathway, is needed to guide clinicians, patients, and policymakers. This plan should involve various stakeholders to ensure inclusive and effective integration of these treatments.